Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Oculus Gets $5.1 Mln Licensing Fee From More Pharma

Oculus Innovative Sciences, Inc. (OCLS: Quote),a California-based nutrition and drug company, Thursday said it received a $5.1 million payment in view of a licensing agreement it executed on August 9, 2012, with More Pharma.

More Pharma had agreed earlier to pay an upfront $5.1 million fee for the exclusive licensing of Oculus' Microcyn-based human healthcare products in Mexico, South/Central America and the Caribbean.

Further, More Pharma will underwrite all costs for regulatory reviews and approval efforts needed for the transition of the marketing and sales effort in the aforementioned countries, said Oculus.

Wednesday, Oculus closed at $0.94 on the Nasdaq.

Click here to receive FREE breaking news email alerts for Oculus Innovative Sciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. said Monday that its fourth quarter profit rose 13% from last year, driven by strong sales of its iPhones and Mac computers. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly sales. At the same time, the company gave an upbeat revenue forecast for the current quarter, which includes the all important holiday season. Stocks moved notably higher over the course of the trading day on Monday, extending the strong upward move seen last Friday. The gains on the day continued the recent recovery by the markets, with the Nasdaq and the S&P 500 closing higher for the third consecutive session. While Republicans have largely tried to frame the upcoming midterm elections as a referendum on President Barack Obama, Sen. Ted Cruz, R-Tex., has joined the few offering guidance on what the GOP will do if it manages to retake control of the Senate.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.